Alain Boudreault

This inventor holds 15 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Aegera Therapeutics, Inc., Pharmascience Inc., Aegera Therpeutics, Inc.. Active years: 2007-2016.

USPTO Granted Patents = 15 (Patent Applications = 1)

% Patents Active = 13.3

CIPO Patents = 1

EPO Patents = 1

Average Co-Inventor Count = 5.7

ph-index = 4

Forward Citations = 42(Granted Patents)

Location History:

Quebec, CA (2010)
Montreal, CA (2007 - 2013)
Dorval, CA (2009 - 2016)

Company Filing History:

8 out of 24

Aegera Therapeutics, Inc.

Aegera Therpeutics, Inc.

patent

Years Active: 2007-2016

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9365614 - IAP BIR domain binding compounds (2016-06-14),

2. 8765681 - IAP BIR domain binding compounds (2014-07-01),

3. 8648094 - IAP BIR domain binding compounds (2014-02-11),

4. 8575113 - BIR domain binding compounds (2013-11-05),

5. 8163792 - IAP BIR domain binding compounds (2012-04-24),

6. 8063095 - IAP BIR domain binding compounds (2011-11-22),

7. 7795298 - IAP BIR domain binding compounds (2010-09-14),

8. 7772260 - [object Object] (2010-08-10),

9. 7772177 - BIR domain binding compounds (2010-08-10),

10. 7741349 - Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides (2010-06-22),

11. 7714003 - [object Object] (2010-05-11),

12. 7645741 - IAP BIR domain binding compounds (2010-01-12),

13. 7579320 - IAP BIR domain binding compounds (2009-08-25),

14. 7547724 - IAP BIR domain binding compounds (2009-06-16),

15. 7230019 - Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides (2007-06-12),

Title: The Innovative Mind of Alain Boudreault

Introduction: Alain Boudreault is a prominent inventor based in Dorval, Canada, known for his remarkable contributions to the field of biotechnology and medicinal chemistry. With a total of 15 patents to his name, Boudreault's work has significantly impacted the development of treatments for various health conditions.

Latest Patents: Among his latest innovations are the IAP BIR domain binding compounds. The first patent details a compound of Formula I or a salt thereof, which includes methods for preparation, along with related methods and compositions. In another related patent, an isomer, enantiomer, diastereoisomer, or tautomer of a compound represented by Formula I or II or a salt thereof is disclosed, focusing on its potential uses in treating proliferative disorders, such as cancer. These patents highlight his commitment to advancing medical science and improving therapeutic options.

Career Highlights: Boudreault's professional journey includes significant tenures at Aegera Therapeutics, Inc. and Pharmascience Inc. These experiences have provided him with invaluable insights into the pharmaceutical industry and have helped him refine his innovative skills.

Collaborations: Throughout his career, Alain Boudreault has collaborated with notable professionals, including James B. Jaquith and Alain Laurent. These collaborations have fostered a dynamic exchange of ideas and further propelled his inventive endeavors.

Conclusion: Alain Boudreault's achievements as an inventor underscore his dedication to innovation and the betterment of healthcare. His work continues to inspire aspiring scientists and inventors in the biotechnology realm, paving the way for future discoveries and advancements.